A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Public ClinicalTrials.gov record NCT03629756. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.
Study identification
- NCT ID
- NCT03629756
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 24, 2018 (Actual)
- Primary completion
- Aug 18, 2021 (Actual)
- Completion
- Sep 3, 2021 (Actual)
- Last update posted
- May 24, 2024
2018 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scottsdale Healthcare Hospitals dba HonorHealth | Scottsdale | Arizona | 85258 | — |
| University of California, Los Angeles | Los Angeles | California | 90024 | — |
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | — |
| Rocky Mountain Cancer Centers (Midtown) | Denver | Colorado | 80218 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| QUEST Research Institute | Royal Oak | Michigan | 48073 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| Prisma Health | Greenville | South Carolina | 29605 | — |
| Texas Oncology, P.A. - Fort Worth Cancer Center | Fort Worth | Texas | 76104 | — |
| Texas Oncology, P.A. - San Antonio Medical Center | San Antonio | Texas | 78240 | — |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | — |
| Medical Oncology Associates dba Summit Cancer Centers | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03629756, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 24, 2024 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03629756 live on ClinicalTrials.gov.